Drug manufacturer Merck today extended its restrictions on 340B pricing involving contract pharmacies to community health centers. The restrictions have applied only to hospital covered entities until now.
Other grantee covered entities remain exempt “at this time,” Merck said, adding
…
340B Report, an independent news organization covering the 340B drug pricing program, is holding its first event—a May 18 webinar about implementing drug manufacturers’ controversial new rules on 340B contract pharmacies. It is an exclusive and free
…
Drug manufacturer Sanofi drew attention this month when it added 45-day time limits for replenishment orders and claims submissions to its conditions on 340B pricing when covered entities use contract pharmacies.
Pfizer and Amgen also recently added similar 45-day lookback requirements
…
Ryan White Clinics for 340B Access (RWC-340B) has asked drug manufacturer Gilead to exempt all Ryan White clinics from the company’s conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies.
RWC-340B made the
…
UPDATE Thursday, April 21, 2022, 5:00 p.m. EDT—AbbVie issued this statement: AbbVie supports the 340B program and is committed to the program’s goal of improving access to medicines for uninsured and vulnerable patients. Our 340B initiative does not block access
…
Drug manufacturer Sanofi has made two major changes to its conditions on 340B pricing when health centers and certain hospitals and use contract pharmacies, a company spokesperson confirms. One is raising flags among 340B providers and the other appears to
…
Bristol Myers Squibb has disclosed its terms of use for the drug claims data that providers must give it in exchange for access to 340B pricing on BMS’s oral oncology drugs Revlimid, Pomalyst, and Thalomid.
BMS acquired the three drugs
…
Astellas Pharma is issuing 340B covered entities refunds for overcharges on three NDCs for its prostate cancer treatment Xtandi and on four NDCs for its overactive bladder medication Myrbetriq for the period from Q3 2020 through Q2 2021.
Astellas posted
Drug manufacturer Lilly is giving 340B covered entities refunds for overcharges on 14 NDCs during Q3 2019 after restating Medicaid average manufacturer prices and best prices “to account for lagged transactional data,” the company says on a notice on the
…
Prescription drug sales at 340B-discounted prices grew 15.9% year-on-year from 2020 to 2021, drug industry consulting and contract research firm IQVIA reports, an annual growth rate below that for the two preceding years.
Last year, IQVIA reported that 340B sales
…*Sign up for news summaries and alerts from 340B Report